Received Sep 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
Flu-like symptoms; Fever; Body aches; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of influenza-like symptoms in a 51-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On 15-SEP-2022, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced influenza-like symptoms (Verbatim: Flu-like symptoms), fever (Verbatim: Fever) and general body pain (Verbatim: Body aches). The outcome of the influenza-like symptoms, fever and general body pain were unknown. It was unknown if the reporter considered the influenza-like symptoms, fever and general body pain to be related to Shingrix. It was unknown if the company considered the influenza-like symptoms, fever and general body pain to be related to Shingrix. Additional Information: GSK Receipt Date: 11-SEP-2025 The pharmacy manager called to inform that a patient got the first dose of Shingrix in 2022 and the patient had experienced flu-like symptoms, fever and body aches, that is why patient did not want the second dose right away. Can patient get the second dose now or does she need to restart the series. After receiving information from MIS, HCP asked the following if a patient had side effects on the first dose, will they experience the same on the second dose.